Reactivation of latent VZV remains a significant cause of morbidity after SCT. Twenty-five percent or more of patients undergoing SCT will experience zoster within the first year after transplant. Short-course (o1 year) prophylaxis with acyclovir has been shown to be effective, but compliance with five times daily dosing may be problematic. We conducted a randomized, double-blind, placebo-controlled trial of valacyclovir (VACV) 1000 mg twice daily from 4 through 24 months after SCT for the prevention of VZV. Fifty-three VZV-seropositive transplant recipients (17 auto-SCT, 36 allo-SCT) were randomized at a median of 163 days after SCT. In a modified intent-to-treat analysis of 49 patients who took study drug, 0 of 22 in the VACV arm experienced zoster reactivation, compared with 6 of 26 (23%) in the placebo arm (P ¼ 0.025). Thirty-two subjects completed therapy through the second year post transplant or first episode of zoster. Adverse events resulting in discontinuation were more frequent in the placebo group (5 of 26 vs 3 of 27 for placebo and study drug, respectively). VACV at a dose of 1000 mg twice daily through 24 months after transplant is well tolerated and effective in suppressing shingles after SCT.
Introduction
After natural infection with VZV (that is, chicken pox), the virus lies dormant in the dorsal root ganglia within the spine.
1,2 During periods of impaired immune surveillance, whether a result of aging, malignancy, or immunosuppression, the virus may reactivate as shingles (herpes zoster). 1, 3, 4 Studies have identified risk factors for the reactivation of VZV infections among SCT recipients including allogeneic transplantation, GVHD, patient age between 10 and 29 years, diagnosis other than chronic myelogenous leukemia and post transplant use of antithymocyte globulin. Among auto-SCT recipients, underlying disease (lymphoma as compared with leukemia or solid tumor) has been identified as a risk factor. 5 Acyclovir (ACV) is a synthetic acyclic purine nucleoside with in vitro inhibitory activity against HSV types 1 and 2 (HSV-1 and HSV-2), VZV, EBV, human herpes virus 6 and CMV. 6 Placebo-controlled trials have shown that oral ACV can significantly reduce the incidence and duration of viral shedding and the overall duration of symptoms in immunocompetent and immunosuppressed patients with HSV and VZV disease. [7] [8] [9] [10] ACV given for up to 12 months after SCT has been shown effective in delaying the occurrence of shingles, but does not affect the overall incidence of outbreaks. [11] [12] [13] [14] [15] [16] [17] [18] [19] Ultimately, the effectiveness of oral ACV for treatment or suppression of disease is limited by poor bioavailability 20 and its short half-life that necessitates frequent (4-5 Â /day) dosing, challenging compliance, particularly with protracted therapy. Valacyclovir (VACV) is the hydrochloride salt of the L-valyl ester of ACV, which is readily absorbed and rapidly converted to ACV in vivo. 21 VACV has shown potent activity against VZV 20 and can be dosed twice daily. We conducted a randomized, double-blind, placebocontrolled, clinical trial of VACV (1000 mg) given twice daily from 4 months through 2 years after autologous or allogeneic transplantation for the prevention of herpes zoster.
Patients and methods
All VZV-seropositive patients undergoing autologous or allogeneic hematopoietic SCT between January 1998 and July 2001 who survived at least 4 months after transplantation were eligible for participation on this trial. Patients who had already developed shingles after transplant and patients with renal impairment (creatinine clearance o50 cc/min) or hepatic dysfunction (SGOT and/or SGPT greater than five times normal limits) were excluded. Approval was obtained from the Institutional Review Board and all subjects gave written informed consent for participation. Subjects were stratified by transplant type (autologous vs allogeneic) and randomized independently to maintain balance between VACV and placebo cohorts. Subjects were randomized to receive either VACV 1000 mg twice daily or matching placebo (supplied by GlaxoSmithKline, Research Triangle Park, NC, USA). The study design was determined by the investigators, and all data were analyzed by the investigators. Subjects were followed according to the routine schedule of the BMT service in the ambulatory setting. Compliance, potential toxicity and occurrence of zoster were assessed at each outpatient visit, which occurred at least monthly in the transplant center or by phone with discussion with study coordinators who monitored patient compliance with pill counts. Study drug was reduced to 500 mg twice daily for the first episode of myelosuppression. Study drug was discontinued for persistent or progressive toxicity at the discretion of the treating transplant physician. Study drug was suspended and antiviral medication given for clinical diagnosis of herpes virus reactivation. Study drug was resumed after successful treatment. Empiric treatment of HSV did not require documentation by culture.
VZV infection was diagnosed clinically in all subjects by the appearance of typical vesicular cutaneous skin lesions. Herpes zoster was defined as VZV infection occurring in an isolated dermatomal distribution. Disseminated VZV was defined as cutaneous involvement of multiple dermatomes and/or visceral involvement. Visceral involvement was implied from evidence of end-organ injury by diagnostic imaging or laboratory screen. Treatment was initiated at the discretion of the clinician caring for the patient.
Statistical analysis
The sample size was based on an estimate of 60% cumulative incidence of zoster among placebo allogeneic BMT recipients over 24 months post transplant, based on our previous study. 21 On the basis of an estimate of effectiveness of 83% in reducing the rate of zoster from 60 to 10% in the VACV arm, we estimated that we would require 17 patients in each arm (power 90%, p0.05).
Zoster events were evaluated on an intent-to-treat basis. Baseline patient characteristics and steroid exposure were compared between the VACV and placebo cohorts using the Wilcoxon signed-rank test for age and steroid exposure and w 2 tests for all other nominal variables. Proportions of subjects developing zoster and toxicity (categorical variables) in treatment and control cohorts were compared using the Fisher's exact test. Unless otherwise stated, P-values p0.05 were considered significant. Zoster-free survival was estimated using the Kaplan-Meier method. Differences in survival were compared using the log-rank test. Statistical analysis was performed using JMP software (SAS Institute, Cary, NC, USA).
Results
Fifty-three VZV-seropositive transplant recipients (17 auto-SCT, 36 allo-SCT) were enrolled and randomized at a median of 163 days (range 92-414 days) after SCT. Table 1 summarizes transplant-related patient characteristics. There were no statistically significant differences between cohorts.
Efficacy
Using an intent-to-treat analysis, the rate of VZV in the VACV arm was 3 of 27 (11%) vs 6 of 26 (23%) in the placebo arm (P ¼ 0.21). All three cases in the VACV arm occurred after randomization but before the subjects started VACV. The median time from randomization to start of study drug was 2 days. Four subjects never started study drug: two developed zoster and two developed myelosuppression before the time they were scheduled to begin; a fifth subject started study drug after resolution of an episode of zoster in violation of study protocol and was removed from further consideration (Figure 1) .
Of the 53 patients randomized, 49 initiated study drug. In our modified intent-to-treat population (mITT) for those who initiated study drug and who were eligible, the rate of zoster was 0 of 22 in the VACV arm vs 6 of 26 (23%) in the placebo arm (P ¼ 0.025). Figure 2a shows the cumulative incidence of zoster for the mITT population. Subjects in the mITT population received study drug for a median of 439 days (range 5-893). There was no difference in the median steroid exposure between cohorts overall: 67 mg months of prednisone vs 52 mg months for placebo and VACV cohorts, respectively (P ¼ 0.7); or for allogeneic subjects only: 115 vs 98 mg months (P ¼ 0.6). The six episodes of zoster in the placebo group occurred at a median of 122 days after randomization (278 days after SCT) and included one case of disseminated involvement. One subject received i.v. ACV for treatment, the others received either ACV or famciclovir orally. The six episodes were complicated by three episodes of post-herpetic neuralgia. Three episodes of zoster occurred in the group randomized to receive VACV at a median of 1 day after randomization and before VACV had been started. There were no complications of VZV reactivation noted in this group. There were no episodes of zoster in the mITT cohort of subjects who were randomized and started study drug.
In a post hoc analysis of those subjects in the VACV and placebo groups who completed the planned drug treatment through 2 years after transplant without zoster, there were two episodes of zoster recorded in the VACV group (2/13) at a median of 11.5 months after discontinuation of VACV and none in the placebo group (0/15) with a median of 8 months follow-up (Figure 2b) . One subject was free of GVHD and off of all immunosuppresion at the time zoster occurred, while the second was receiving mycophenolate and 15 mg prednisone daily. Episodes were treated with i.v. ACV and oral famciclovir, respectively without complication. Steroid dosing as a marker of immunosuppression at the conclusion of the study period in those who completed the study was similar between groups: median 0 mg daily (range 0-30 mg) and 7.5 mg (range 0-20 mg) in the VACV and placebo groups, respectively. Tolerability Thirty-two subjects (VACV 14, placebo 18) completed the planned therapy through the second year after transplant or first episode of zoster. Reasons for discontinuation other than zoster in the placebo group included adverse reactions attributed to blinded study drug by the treating physician (nausea/vomiting/dehydration in two subjects; elevated transaminases, low plts, and joint pains in one subject each) and relapse (four) ( Table 2 ). Reasons for discontinuation in the VACV group included non-compliance/ withdrawal of consent unrelated to adverse events (five), relapse (two) and adverse reactions attributed to study drug (two leukopenia, one cramping abdominal pain).
Study drug was suspended in three subjects in the VACV group for the occurrence of HSV infection. Subjects were diagnosed clinically, based on the presence of vesicular Valacyclovir prophylaxis in BMT A Klein et al lesions on the labia or hard palate. In all three subjects, the lesions appeared concurrent with worsening of described oral chronic GVHD. The subjects were treated with oral famciclovir for up to 3 months concurrent with increases in immunosuppression for GVHD. Lesions in all three resolved without sequellae. No cultures were obtained to confirm HSV infection.
Discussion
In spite of the advances in antiviral therapy, reactivations of latent herpes virus infections, including VZV, remain significant causes of morbidity and mortality after autoand allo-SCT. Twenty-five percent or more of patients undergoing SCT will reactivate latent VZV in the form of shingles within the first year after transplant, occurring at a median of 5 months. 5, [22] [23] [24] [25] [26] Mortality because of VZV infection has reduced dramatically after the widespread availability of effective antiviral therapy. 5, 26 Approximately 30% of reactivations will be complicated by post-herpetic neuralgia, cranial nerve sequelae (visual loss, tinnitus, persistant nerve palsies) or cutaneous and/or visceral dissemination resulting in acute and chronic pain, and disability. 26 In a previously published report from our center on 100 sequential patients undergoing allogeneic transplant at this institution without antiviral prophylaxis, 41% suffered reactivation of VZV, including 59% of those surviving at least 2 years after transplant. 22 The most common complication was neuralgia in 41% of those reactivating. Three patients developed bacterial superinfection and two developed central nervous system involvement, one of whom died of encephalitis.
In this trial, we showed that VACV given in a dose of 1000 mg orally twice a day for 2 years, beginning 4 months after BMT, can effectively eliminate VZV reactivation. However, once discontinued a few cases did occur more than 24 months post transplant. In our trial, reactivation of VZV occurred in two phases in the group randomized to receive VACV. Unfortunately, three reactivations occurred at a median of 1 day after enrollment and randomization, but before starting study drug for prophylaxis. This clustering among the VACV patients must be considered a chance event, because subjects were approached for participation in this trial starting 4 months after transplant without any knowledge of treatment assignment. In contrast, VZV reactivations in the placebo group were distributed more evenly over time.
In addition, a post hoc analysis of those subjects who completed the planned treatment on this trial revealed a second phase of VZV reactivations in 2 of 13 (15%) VACV recipients, at 3 and 8 months after discontinuing treatment (median of 15.5 months follow-up). There were no reactivation episodes in the placebo cohort (median of 8 months follow-up). Although the numbers are too small for any conclusions, the fact that reactivation did occur in the treatment group after discontinuation, in spite of the very long-term VACV exposure, suggests that prophylaxis did effectively suppress VZV, but did not allow the immune system to prevent subsequent reactivation, even after 20 months.
This trial was planned and initiated before the availability of significant experience with long-term use of VACV. Several single arm trials have been reported in the interim showing equivalent tolerance and/or efficacy at doses ranging between 3 and 8 g daily for up to 30 days. [27] [28] [29] [30] Published experience with VACV in an extended prophylaxis setting remains limited. 31, 32 VACV 500 mg twice daily has been given preferentially over ACV to patients with intensive steroid exposure for the prevention of VZV by the Seattle group. 12 Pharmacokinetic studies 21 would predict a VACV dose of 500 mg daily might provide a dose that should have an effect comparable to ACV at a dose of 400 mg daily or higher. ACV at a dose of 200 mg daily given prospectively for prevention of VZV has been similarly effective in preventing zoster. 33 Although experience now indicates that VCV at a dose of 1000 mg twice daily is likely more than sufficient to prevent reactivation, it is nonetheless reassuring to note that toxicity attributable to VACV was minimal in this trial. Discontinuations for adverse reactions attributed by the treating physician to study drug were similar in both arms, 21% in the VACV arm and 29% in the placebo arm.
VZV prophylaxis is not routinely recommended by guidelines of the Centers for Disease Control, 34 yet has been adopted as standard of care at many institutions. Eradication of VZV or long-term suppression after therapy has proven elusive. Complete suppression of VZV activity may deprive the recovering immune system of the Ag exposure required to boost anti-VZV immunity. Thus, while prophylaxis will not eliminate the risk of reactivation, it may be used strategically to delay the eventual onset of shingles until a patient is more 'fit' to handle the infection. 'Fitness' in this context would reflect the clinical status of the patient in the moment, influenced by the severity of risk factors associated with reactivation including GVHD and 
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